Physician profile
Nitin Gupta
NPI 1962454835
$6,477.61
in general payments reported to CMS, 2019-2025
26 companies · $1,138 in 2025
The $1,138 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $338 · 2021: $470 · 2022: $1,642 · 2023: $912 · 2024: $1,209 · 2025: $1,138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,258.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $2,062.32 | 2019-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $1,282.08 | 2019-2024 | Vabysmo |
| Onmark, INC. | $870.33 | 2022 | |
| Abbvie INC. | $413.52 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $253.29 | 2019-2021 | |
| Alcon Vision LLC | $243.74 | 2021-2022 | |
| Astellas Pharma US INC | $225.88 | 2023-2025 | Izervay |
| Allergan, INC. | $192.18 | 2019-2021 | |
| Harrow Eye, LLC | $183.09 | 2025 | Iheezo, Triesence |
| E.R. Squibb & Sons, L.L.C. | $122.04 | 2020 | |
| Ocular Therapeutix, INC. | $88.80 | 2019 | |
| Biogen, INC. | $84.54 | 2022-2023 | |
| Notal Vision, INC. | $81.52 | 2024 | Foresee Home |
| Apellis Pharmaceuticals, INC. | $71.90 | 2022-2024 | Syfovre |
| Coherus Oncology, INC. | $59.57 | 2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyepoint US, INC. | $45.02 | 2022 | |
| Alimera Sciences, INC. | $41.04 | 2022-2023 | Iluvien |
| Sandoz INC. | $32.02 | 2024 | Cimerli |
| Bausch & Lomb Americas INC. | $23.23 | 2023 | Xipere, Visudyne |
| Ani Pharmaceuticals, INC. | $23.07 | 2025 | Iluvien |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Hospital Products INC. | $18.48 | 2022 | |
| US Oncology Corporate, INC. | $18.09 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $11.44 | 2019 | |
| Mckesson Specialty Care Distribution, LLC | $11.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nitin Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.